SMPD2 (sphingomyelin phosphodiesterase 2) is a neutral sphingomyelinase that hydrolyzes sphingomyelin into ceramide and phosphocholine. It plays critical roles in cellular signaling, apoptosis, and membrane remodeling . The FITC-conjugated SMPD2 antibody is a fluorescently labeled immunoglobulin designed to detect and visualize SMPD2 protein in cells. FITC (fluorescein isothiocyanate) enables real-time localization studies via microscopy, making it essential for immunofluorescence (IF) and immunocytochemistry (ICC) .
SMPD2 knockdown (KD) induces G1 phase arrest by upregulating cyclin-dependent kinase inhibitors (P21, P27) and reducing phosphorylated Akt levels, impairing PI3K/Akt signaling . FITC-conjugated antibodies are pivotal in tracking SMPD2 localization during cell cycle progression.
SMPD2 KD impairs the unfolded protein response (UPR) under ER stress, reducing LAMP1 mRNA/protein levels without affecting lysosomal acidification. This highlights SMPD2’s role in buffering ER stress .
Wnt Signaling: SMPD2 KD reduces β-catenin and Wnt3a levels, disrupting canonical Wnt signaling .
PI3K/Akt Pathway: Reduced phosphorylated Akt levels upon SMPD2 KD correlate with diminished cell proliferation .
Primary Antibody: Incubate overnight with FITC-conjugated SMPD2 antibody (e.g., 5–20 µg/ml for Abbexa) .
Secondary Detection: FITC-conjugated secondary antibodies (e.g., 1:200 dilution) .